

Novel mechanism uncovered: PRMT1 advances gastric cancer progression via βcatenin signaling

October 9 2023



PRMT1 is highly expressed in gastric cancer (GC) and is associated with a poor prognosis. (A–D) Box plots showing PRMT1 expression levels in gastric tissue and gastric adenocarcinoma (A), gastric tissue and gastric cancer (B), gastric mucosa and gastric intestinal-type adenocarcinoma (C), and gastric mucosa and gastric mixed adenocarcinoma (D) in the Oncomine database with the indicated log-rank test P values. (E, F) Box plots showing PRMT1 expression levels in



normal tissue and primary tumors (E) and normal tissue at different grades of the stomach adenocarcinoma (STAD) dataset (F) in the TCGA database. (G) The expression of PRMT1 in a normal gastric tissue cell line (the GES-1 cell line) and five GC cell lines (the BGC-823, HGC-27, MGC-823, MKN-45, and SGC-7901 cell lines) was examined by Western blot assay. (H) Overall survival curve analysis of progression-free survival of GC patients based on data obtained through the Kaplan–Meier plotter tool with the indicated log-rank test P values. (I) Immunofluorescence assays were performed to determine the subcellular localization of PRMT1. (J) IHC for PRMT1 expression in six normal tissues and thirty-six gastric cancer tissues. Scale bar = $10 \,\mu m$ **P

Citation: Novel mechanism uncovered: PRMT1 advances gastric cancer progression via βcatenin signaling (2023, October 9) retrieved 12 May 2024 from https://medicalxpress.com/news/2023-10-mechanism-uncovered-prmt1-advances-gastric.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.